![Cancers | Free Full-Text | Real-World Impact of SABR on Stage I Non-Small-Cell Lung Cancer Outcomes at a Scottish Cancer Centre Cancers | Free Full-Text | Real-World Impact of SABR on Stage I Non-Small-Cell Lung Cancer Outcomes at a Scottish Cancer Centre](https://www.mdpi.com/cancers/cancers-15-01431/article_deploy/html/images/cancers-15-01431-g001.png)
Cancers | Free Full-Text | Real-World Impact of SABR on Stage I Non-Small-Cell Lung Cancer Outcomes at a Scottish Cancer Centre
![PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7cbf64e0a2a5bc6572dc331e433efae660922309/4-Figure1-1.png)
PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar
![Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-020-06738-z/MediaObjects/12885_2020_6738_Fig3_HTML.png)
Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text
![Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data](https://www.archivesofmedicalscience.com/f/pictures/99749_28bf0.jpg)
Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data
![5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/96376398-fbed-4daa-bd31-dd6b9854d8fc/gr3.jpg)
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
Tumor Treating Fields Plus Standard of Care Improved Overall Survival Among Patients With Metastatic Non-Small Cell Lung Cancer on Vimeo
![Overall survival by clinical stage according to the seventh edition (A)... | Download Scientific Diagram Overall survival by clinical stage according to the seventh edition (A)... | Download Scientific Diagram](https://www.researchgate.net/publication/298712242/figure/fig1/AS:858846075568128@1581776269653/Overall-survival-by-clinical-stage-according-to-the-seventh-edition-A-and-the-proposed.png)
Overall survival by clinical stage according to the seventh edition (A)... | Download Scientific Diagram
![The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion | Scientific Reports The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-022-17918-1/MediaObjects/41598_2022_17918_Fig3_HTML.png)
The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion | Scientific Reports
![Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology](https://www.thelancet.com/cms/attachment/755a9194-decd-44b1-8d75-55329dccf733/gr1_lrg.jpg)
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology
![Histological Grade: Analysis of Prognosis of Non-small Cell Lung Cancer After Complete Resection | In Vivo Histological Grade: Analysis of Prognosis of Non-small Cell Lung Cancer After Complete Resection | In Vivo](https://iv.iiarjournals.org/content/invivo/32/6/1505/F1.large.jpg)
Histological Grade: Analysis of Prognosis of Non-small Cell Lung Cancer After Complete Resection | In Vivo
![5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/f29f5c3e-5a9b-447a-8641-63022e061899/gr1_lrg.gif)
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
![Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis | Radiation Oncology | Full Text Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis | Radiation Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13014-019-1222-3/MediaObjects/13014_2019_1222_Fig1_HTML.png)
Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis | Radiation Oncology | Full Text
![File:Overall survival in non-small lung cancer patients treated with modern immunotherapy in the first line for advanced or metastatic disease.jpg - Wikimedia Commons File:Overall survival in non-small lung cancer patients treated with modern immunotherapy in the first line for advanced or metastatic disease.jpg - Wikimedia Commons](https://upload.wikimedia.org/wikipedia/commons/5/5a/Overall_survival_in_non-small_lung_cancer_patients_treated_with_modern_immunotherapy_in_the_first_line_for_advanced_or_metastatic_disease.jpg)
File:Overall survival in non-small lung cancer patients treated with modern immunotherapy in the first line for advanced or metastatic disease.jpg - Wikimedia Commons
![Clinical trial shows significant disease-free survival for patients diagnosed with non-small cell lung cancer Clinical trial shows significant disease-free survival for patients diagnosed with non-small cell lung cancer](https://scx1.b-cdn.net/csz/news/800a/2023/clinical-trial-shows-s.jpg)
Clinical trial shows significant disease-free survival for patients diagnosed with non-small cell lung cancer
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis | PLOS ONE
![EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan](https://www.spandidos-publications.com/article_images/ol/18/6/ol-18-06-6090-g02.jpg)
EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan
![Cancers | Free Full-Text | Immune Checkpoint Inhibitors after Radiation Therapy Improve Overall Survival Rates in Patients with Stage IV Lung Cancer Cancers | Free Full-Text | Immune Checkpoint Inhibitors after Radiation Therapy Improve Overall Survival Rates in Patients with Stage IV Lung Cancer](https://pub.mdpi-res.com/cancers/cancers-15-04260/article_deploy/html/images/cancers-15-04260-g001.png?1692958885)
Cancers | Free Full-Text | Immune Checkpoint Inhibitors after Radiation Therapy Improve Overall Survival Rates in Patients with Stage IV Lung Cancer
![A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health](https://www.thelancet.com/cms/asset/0fbe43e7-b69c-43d2-bff9-10ce650542f3/gr1.jpg)
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health
![Overall survival of 1466 non-small cell lung cancer patients according... | Download Scientific Diagram Overall survival of 1466 non-small cell lung cancer patients according... | Download Scientific Diagram](https://www.researchgate.net/publication/317189811/figure/fig3/AS:613891981709346@1523374662976/Overall-survival-of-1466-non-small-cell-lung-cancer-patients-according-to.png)